EDIT — Editas Medicine, Inc.
Is EDIT overbought or oversold? Here is the current MarketMoodz read.
Editas Medicine, Inc. (EDIT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.87. The rating moved from Overbought to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.87
- Last changeMoved from Overbought to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Editas Medicine, Inc. (EDIT) is a gene‑editing–focused biotech with potentially high upside tied to clinical and regulatory catalysts, but it carries material near‑term financing and execution risk. The company's valuation is sensitive to binary trial readouts and partnership activity; favorable sector risk‑on flows could support short‑term upside, while clinical setbacks, manufacturing/regulatory delays, or the need to raise capital would likely pressure the shares. Competitive pressures from other gene‑editing developers and the broader convertible/debt financing dynamics in biotech increase the probability of dilution and cyclical volatility. The medium‑term outlook depends on clinical progress, capital strategy, and any near‑term partnership or licensing developments.
Key factors
- Pipeline potential: gene-editing programs with binary clinical/regulatory catalysts that could materially re-rate valuation if positive.
- Capital needs and cash runway: high R&D spend typical of early/mid‑stage biotech increases likelihood of near-term financing requirements.
- Competitive landscape: strong competition from other gene‑editing and gene‑therapy companies increases commercial and scientific risk.
- Regulatory risk and complexity: therapies in this space face stringent safety and manufacturing/regulatory hurdles that can cause delays.
- Market environment: risk‑on sentiment and growth‑focused flows may provide short-term uplift for speculative biotech names.
- Sector financing headwinds: convertible‑debt and dilution pressures in biotech could increase hedging and share issuance risk.
Risks
- Clinical trial failures or missed endpoints for lead programs, causing sharp share price declines.
- Dilution from equity raises or convertible financings if cash runway is insufficient to reach key inflection points.
- Regulatory setbacks, manufacturing issues, or safety signals that delay approvals or commercialization.
- Intense competition from better‑capitalized peers, reducing potential market share and partnership appeal.
- Intellectual property disputes or licensing complications that affect freedom to operate.
- Low trading liquidity and high volatility leading to exaggerated price moves and execution risk.
See today's live rating, score and targets
Members see the live hourly rating for EDIT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.